Tracking a rare blood disorder treatment in Real-World patients

This study will observe how well the medication ravulizumab works for Polish patients with atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder that can damage the kidneys. Researchers will follow about 80 patients already receiving this drug as part of their standard care under a national program. The goal is to collect real-world information on how patients respond to treatment, including improvements in blood counts, kidney function, and quality of life.